



The e-newsletter for the Indian Biotech industry

www.ableindia.in

June 2026 | Issue 0025

## ABLE Governing Body Members

Hon. Non-executive Chairperson  
Dr. Kiran Mazumdar-Shaw

Hon. President  
Mr. G S Krishnan

Hon. Vice President  
Ms. Deepanwita Chattopadhyay

Hon. General Secretary  
Dr. Ezhil Subbian

Treasurer  
Mr. Ravi Bhola

### Governing Body members

Dr. Ashvini Shete

Dr. B N Manohar

Dr. Jayashree Aiyar

Mr. Krishna Kalyan T. D.

Mr. Sanjeev B Neelappa

Dr. S. Shriram


Ms. Sowmya L Balendiran

Dr. Vasam Sambandamurthy

Mr. Venkat K Bundla

Advisor & Editor  
Mr. Narayanan Suresh

## India Pavilion @ BIO San Diego showcases India biotech to the world



**Dear Members, Colleagues and Friends,**

I am very happy to inform members that the 5,000 sq. ft **India Pavilion**, set up by ABLE, at the **BIO International Convention in San Diego, USA, from June 22-25, 2026**, has achieved the primary objective of show casing the best from our industry to the world. This is the largest ever India Pavilion at this world's biggest biotech event, since the country started participating in it 24 years ago.

The Pavilion remained a beehive of activities till closure time on 25th afternoon. All the participants reported conducting lots of business meetings inside the Pavilion using the Exhibitor Partnering tool. This is one of the reasons, companies keep coming back to our India Pavilion, to engage with the global business leaders in biotech.

The **100+** India delegation, from **50** exhibitors that included top vaccine makers, CROs, startups, state governments, was boosted by the presence of India's Consul General in Los Angeles, Ambassador Dr. K.J. Srinivasa, who inaugurated the Pavilion and interacted with all the participants. To understand the offerings from the industry and absorb the innovative strides that could be passed on to companies that contact our national outpost in California and beyond.

India Pavilion had a new feature this time with the **BioVoices** program that had some of our companies talking about their innovations to the global audience in curated sessions daily. ABLE also organized a visit of delegates, coordinated by our partner Carve Labs, to meet the leadership in **California** Governor's office, leaders of key states cities and regions like **Philadelphia, Maryland, Massachusetts** besides interaction with researchers at **illumina** headquarters.

The momentum built by this year's **India Pavilion** will continue next year in **June @ BIO Philadelphia** with 5000 sq. ft already booked. I request all member companies and other participants to sign up the best slots early, confirm your participation to organize much bigger delegation visits to key institutions in the tri-state area adjoining Philadelphia that is one of leading regions for biotech innovations in the USA.

**G S Krishnan**  
**Hon. President, ABLE**

## IN THIS ISSUE

- Biggest India Pavilion @ BIO 2026 draws global attention
- India Biotech Handbook 2026 Released at BIO International Convention 2026
- BioVoices @ India Pavilion: Showcasing Indian Biotech Innovation at BIO 2026
- ABLE & Carve Startup Labs Lead India Biotech Delegation to the USA during BIO 2026
- ABLE participates in the ICBA annual meeting at BIO 2026
- Thank You to Our Exhibitors at the India Pavilion, BIO 2026
- Join the India Pavilion at BIO International Convention 2027

# Biggest India Pavilion @ BIO 2026 draws global attention

By Narayanan Suresh



**India's Consul General in Los Angeles, Ambassador Dr. K.J. Srinivasa**, inaugurated the India Pavilion at the world's biggest biotech event, the BIO International Convention in San Diego, California, USA, on 22nd June 2026 in the presence of over 100 biotech industry leaders from 50+ companies and international participants. The 5000 sq ft India Pavilion was set up by the Association of Biotechnology Led Enterprises (ABLE).

**Mr. G S Krishnan, Hon. President, ABLE**, welcomed the Consul General and shared the impressive strides made by the \$195 billion national BioEconomy with the global audience. Dr. Srinivasa, in his inaugural address, sought global investments into India's growing BioEconomy and highlighted some of the major policy thrusts of the government of Prime Minister Narendra Modi to make India an attractive destination for foreign capital.

The Consul General released the **India Biotech Handbook 2026**, brought out by ABLE to showcase the strengths of India's BioEconomy industry.

**Dr. Chhaya Chauhan**, Chief Manager & Incharge – Incubation, Biotechnology Industry Research Assistance Council (BIRAC), highlighted India's growing biotechnology ecosystem and emphasized the pivotal role of innovation, entrepreneurship and global partnerships in positioning the country as a leading hub for biotechnology and life sciences.

## IN THIS ISSUE

- Join us for the Webinar on “Commercializing In-Space Biomanufacturing: Global Market Evidence and Opportunities for the Pharmaceutical Industry”
- Highlights of the webinar “Axiom Mission 4 – Enabling International Collaboration and Biomedical Innovation in Space” held on 22<sup>nd</sup> May
- Highlights of the webinar “Indo-Iowa-U.S. Biosciences Collaboration” held on 11<sup>th</sup> June
- Industry News

Concluding the India Pavilion inaugural function, **Mr. Narayanan Suresh, Advisor, ABLE** informed that this year’s 5000 sf ft India Pavilion was the biggest exhibition area set up by the country since it began participating in this global event from 2001. He thanked all the companies who wholeheartedly participated in the India Pavilion to make it a cynosure of the global industry.

**Dr. Balasubramanya S, GM, ABLE** compered the event and other major in-pavilion activities in the Pavilion over the 4 days of the event from June 22-26, 2026 at the San Diego Convention Center.

India Pavilion saw huge footfalls during the 4 days, and almost all the participating companies reported having 20 to 25 useful meetings with global clients, using the event’s Partnering System, facilitated by ABLE within the India Pavilion. The Pavilion was full of activity on all four days, till the closure time and visitors savoured on the popular Masala Tea and snacks from India.

ABLE also organized a visit for Indian participants to the global headquarters of Illumina, the maker of gene sequencing and other key equipment, used widely by the industry.

**The Bio Conference** also celebrated the 50th year of the emergence of the modern biotech industry that started with the founding of Genentech in the San Francisco area in 1976 from Stanford University graduates.

The conference had more than 150 sessions and 1000+ speakers over the four days. The sessions focused on 18 key areas, from AI (artificial intelligence) and digital health to diagnostics and personalized medicine, emerging opportunities in global markets, and more. Leading biotech executives, investors, service providers, government officials, regulators, and patient advocates representing the full ecosystem of biotechnology connected over four days of networking, programming, and partnering.

BIO leaders said more than 10,000 partnering delegated conducted 70,000+ meetings in the special zone for this activity.

“The BIO International Convention unites the world of biotechnology with great purpose,” said **Mr. John F. Crowley, President & CEO of BIO**. “As we celebrate 50 years of our biotechnology industry, this year’s convention brings together innovators, entrepreneurs, public health officials, and patient advocates prepared to tackle the hardest scientific challenges and to save and change lives for the next 50 years and more. This year’s theme ‘**Driven by Purpose**’ exemplifies what drives everyone in biotechnology – and will ensure we continue to drive the miracles of modern medicine needed to save and improve lives worldwide for the 21st century and beyond.”

The event theme this year was “**Driven by Purpose**,” the future of biotechnology innovation, and the growing role of AI in scientific innovation. BIO continued the special AI Summit, started last year, this time too to discuss ways to leverage the technology to speed up biotech innovation. A BIO “**Story Telling Stage**” Provided innovative startups from all countries to share their work with the audience. In all, 60 country pavilions were set up in the event. China returned with low key presence to the event after few years. Saudi Arabia had a big presence in the exhibition and also conference sessions.

Notable speakers and moderators at BIO 2026 included **Gary Sinise**, actor, humanitarian, and founder of the Gary Sinise Foundation; Head Coach of the University of Notre Dame **Marcus Freeman**; **Ashley Magargee**, CEO of Genentech; **Kimberly Powell**, Vice President of Healthcare at NVIDIA; award-winning journalist **Katie Couric**; BIO Board Chair **Fritz Bittenbender**, Senior Vice President and Head of Public Affairs & Access at Genentech; **Gov. Tina Kotek**, Oregon; **Michael Davis**, MD, PhD, Acting Director, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA); **Karim Mikhail**, B.Pharm, MSc, Acting Director, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA); **Lowell Zeta**, JD, Acting Chief of Staff, Officer of the Commissioner, U.S. Food and Drug Administration (FDA); **Rafid Fadul**, MD, MBA, Chief Medical Officer, U.S. Advanced Research Projects Agency for Health (ARPA-H); and INDY NXT by Firestone driver **James Roe**.

Other notable speakers include:

- **Minister Preet Kaur Gill**, Parliamentary Under-Secretary of State, U.K. Department of Health and Social Care
- **Lawrence Tallon**, Chief Executive, U.K. Medicines and Healthcare products Regulatory Agency (MHRA)
- **Emer Cooke**, Executive Director, European Medicines Agency (EMA)
- Steffen Thstrup, PhD, Chief Medical Officer, European Medicines Agency (EMA)
- **Her Excellency Dr. Noura Al Ghaiti**, Undersecretary of the Department of Health, Abu Dhabi
- **His Excellency Khalid Alburikan**, Deputy Minister of Health for Investment, Ministry of Health, Kingdom of Saudi Arabia
- **Sandra Gallina**, Director-General for Health and Food Safety, European Commission
- **Robert Langer**, ScD, Executive Chairman & Chair of Scientific Advisory Board, T.Rx Capital; Institute Professor, Massachusetts Institute of Technology

**Some of the key learning from different conference sessions:**

- AI tools could be used smartly by biotech companies not just in drug discovery process but also to speed up clinical trials significantly
- Biotech industry globally has started gaining global investor attention after a 3-year deal with significant investment announcements. Eg: a \$ 2.5 billion deal

between **Insilico Medicine** and **SK Pharmaceuticals** to speed up AI-driven drug discovery

- Impressive strides made by innovative biotech entrepreneurs should be watched closely. More than \$135 billion invested by Chinese companies last year
- Experts predicted that a Takeda-like global MNC in biotech will emerge from China within the next 10 years
- There was a strong view that global investors with deep pockets could gain edge by out licensing innovative products developed by China-based innovators early, scale up and manufacture in USA, Europe and India to capture the full value quickly and enhance reach to patients globally.
- Japan has unveiled a national plan to manufacture at home, 700 critical APIs (active pharmaceutical ingredients) to shore up health security of citizens and reduce supply constraints caused by global events.




# India Biotech Handbook 2026 Released at BIO International Convention 2026



The **India Biotech Handbook 2026**, published by the **Association of Biotechnology Led Enterprises (ABLE)**, was officially launched at the BIO International Convention 2026 in San Diego, USA by **Ambassador Dr. Srinivasa K. J., IFS, Consul General of India in Los Angeles**.

The release took place in the presence of **Mr. G S Krishnan**, Hon. President, ABLE; **Dr. Chhaya Chauhan**, Chief Manager & Incharge – Incubation, BIRAC; **Dr. Debanjana Dey**, Senior Program Manager – Technical, BIRAC; **Dr. Balasubramanya S.**, General Manager, ABLE; and **Mr. Narayanan Suresh**, Advisor, ABLE.



The India Biotech Handbook 2026 presents a comprehensive overview of India's dynamic biotechnology ecosystem, showcasing the country's capabilities across BioPharma, BioIndustrial, BioAgri, BioServices, MedTech, Startups, Innovation, Research Infrastructure, and Investment Opportunities. The publication serves as a valuable resource for global industry leaders, investors, researchers, policymakers, and other stakeholders seeking to engage with India's rapidly growing biotechnology sector.

[Click here to download the file](#)

## BioVoices @ India Pavilion: Showcasing Indian Biotech Innovation at BIO 2026



As part of the BIO International Convention 2026 in San Diego, USA, ABLE successfully organized **BioVoices @ India Pavilion**, an exclusive platform that enabled Indian biotechnology companies to present their innovations and capabilities to a global audience.

The session featured presentations by **Raptim Research Pvt. Ltd.** and **AAARNA Therapeutics**, who showcased their cutting-edge technologies, research expertise, products, and collaboration opportunities before an audience comprising international delegates, exhibitors, investors, and industry leaders. The presentations sparked engaging discussions and opened avenues for strategic partnerships and global collaborations.

Through initiatives like these, ABLE continues to support Indian biotech enterprises in expanding their global footprint and positioning India as a preferred destination for biotechnology innovation.

---

## ABLE & Carve Startup Labs Lead India Biotech Delegation to the USA during BIO 2026

**ABLE in collaboration with Carve Startup Labs**, organized an exclusive **India Biotech Delegation to the United States**, providing Indian biotechnology companies with direct exposure to one of the world's most advanced life sciences and innovation ecosystems.

The delegation participated in a series of curated engagements with leading organizations and innovation stakeholders, including **Illumina Headquarters**, the **California Governor's Office of Business and Economic Development (GO-Biz)**, the **Department of Commerce**, **City of Philadelphia**, the **Maryland Department of Commerce**, **Massachusetts life sciences stakeholders**, Beyond Bio meeting organized by **Institute for the Global Entrepreneur (UC San Diego)**, **ABI-LAB** and several U.S. Economic Development Organizations (EDOs) and ecosystem partners.

These interactions provided delegates with valuable opportunities to present their technologies, gain first-hand insights into the U.S. biotechnology landscape, understand market entry and commercialization strategies, receive expert feedback, and explore collaborations with industry leaders, investors, accelerators, and government agencies. The programme also enabled participants to better understand regulatory expectations, innovation support mechanisms, and business expansion opportunities available across key U.S. biotechnology clusters.

The delegation served as an important platform for strengthening India–U.S. biotechnology collaborations and fostering long-term partnerships that can accelerate innovation and global growth for Indian biotech enterprises.

*If you are a biotech startup, innovator or company looking to explore global markets, we'd be delighted to have you join our upcoming international delegations. Please reach out to us for more information.*



## **ABLE participates in the ICBA annual meeting at BIO 2026**

ABLE participated in the International Council of Biotechnology Associations (ICBA) Annual Meeting, held alongside the BIO International Convention 2026 in San Diego, USA. Representing ABLE, **Dr. Balasubramanya S.**, General Manager, and **Mr. Narayanan Suresh**, Advisor, joined biotechnology association leaders from around the world to discuss emerging trends, strengthen international collaborations, and explore opportunities to advance innovation and growth within the global biotechnology ecosystem.

ABLE is one of the co-founders of ICBA that now has 35+ national biotech industry associations as members. ICBA members meet virtually every month to discuss various issues faced by the biotech industry and prepare plans to present a unified face to national and global policy makers and regulators to ensure a smooth sailing for the industry. In the last two years, ICBA has focused on ensuring resilience of global pharmaceutical supply chains. Previously, ICBA prepared a white paper on the issue of Anti-Microbial Resistance.

During the annual meeting, **Mr. Suresh** shared details of the latest biotech trends in the country such as the huge patient response to the generic versions of GLP-1 class of drugs since March 2026 as it went off patent, the Indian regulators efforts to harmonize the processes of clinical trials. He informed the members about the US FDA approval to an India-made antibiotics to treat urinary tract infections. This is the first new antibiotic approved globally in the last 50 years.

Mr. Suresh also presented the India story at **the ICBA Round Table on “Global Supply Chain Resiliency for Biopharmaceutical Innovations,”** conducted on June 22, 2026 in the BIO Conference session. He spoke about the high inter-connectedness of the pharmaceutical industry and gave examples of changes in national directives to vary production of some ingredients create global supply shortages.

Top regulators from Japan and European Union presented the steps taken by their governments to maintain stability of global supply chains that are key to pharmaceutical manufacturing.



# Thank You to Our Exhibitors at the India Pavilion, BIO 2026

ABLE extends its heartfelt thanks to all the exhibitors who participated in the **India Pavilion at the BIO International Convention 2026 in San Diego, USA.**

We sincerely thank all our exhibitors, delegates, partners, government representatives and visitors for making the India Pavilion a resounding success. Your enthusiasm, collaboration and commitment continue to strengthen India's position as a leading global biotechnology destination.

We look forward to welcoming you again at the **India Pavilion, BIO International Convention 2027 in Philadelphia, USA.**



## Join the India Pavilion at BIO International Convention 2027

Following the tremendous success of the India Pavilion at BIO International Convention 2026 in San Diego, ABLE is delighted to announce that it has once again secured exhibition space to organize the **India Pavilion at the BIO International Convention 2027**, to be held in **Philadelphia, Pennsylvania, USA**, from **7–10 June 2027**.

The India Pavilion will continue to serve as a premier platform for Indian biotechnology companies, startups, research organizations, and innovation stakeholders to showcase their technologies, products, and capabilities to a global audience of industry leaders, investors, researchers, and policymakers. It offers unparalleled opportunities for business networking, strategic partnerships, collaborations, and international market expansion.

**Organizations interested in exhibiting at the India Pavilion are encouraged to reserve their space early.** For exhibition bookings and further details, please contact: **Dr. Balasubramanya S.**, General Manager, ABLE ([gm@ableindia.org.in](mailto:gm@ableindia.org.in))

**We look forward to welcoming you to the India Pavilion at BIO 2027. See you in Philadelphia!**



P H I L A D E L P H I A

# Join us for the Webinar on “Commercializing In-Space Biomanufacturing: Global Market Evidence and Opportunities for the Pharmaceutical Industry”



## Commercializing In-Space Biomanufacturing

Global Market Evidence and Opportunities for the Pharmaceutical Industry

The Center of Excellence (CoE) Space Tech Foundation Bangalore is organizing a series of webinars under “Space to Society” along with ABLE



10 JULY 2026 | 06:00 - 07:30 PM (IST)



**Dr. Maulesh Gadani**  
ISRO



**Mari Anne Snow**  
Easra Biotech



**Dr. Pavel Ryzhov**  
Space Biotech Hub



**Ecem Badruk**  
Women in Space Biotech  
(Moderator)

REGISTER NOW




The **CoE SpaceTech Foundation, Bengaluru**, in collaboration with **ABLE** (as the Biotech Industry Knowledge Partner) and **Helogen Corporation** (as the Industry Partner), invites you to the fourth webinar in the **Space to Society** webinar series on **10<sup>th</sup> July 2026** from **06:00 – 07:30 PM (IST)**.

Register here: <https://shorturl.at/hdAKM>

This webinar will explore how space is emerging as the next frontier for pharmaceutical R&D and biomanufacturing, highlighting the commercial potential of microgravity in drug discovery, biologics, advanced therapeutics, and nanoparticle manufacturing. Experts from government, industry, and the global space biotechnology ecosystem will share real-world case studies, discuss business opportunities, and examine how India's Human Spaceflight Programme and future Indian Space Station can accelerate innovation through collaborations between industry, academia, startups, and space agencies.

## Highlights of the webinar “Axiom Mission 4 – Enabling International Collaboration and Biomedical Innovation in Space” held on 22<sup>nd</sup> May



The third webinar in the **"Space to Society"** series, was organized by the **Centre of Excellence (CoE) Space Tech Foundation**, in collaboration with **ABLE** (as the Biotech Industry Knowledge Partner) and **Helogen Corporation** (as the Industry Partner) on 22<sup>nd</sup> May. The webinar attracted participants from over 14 countries, including representatives from the biotechnology, pharmaceutical, healthcare, academia, research and space sectors, reflecting the growing global interest in commercial space research and biomanufacturing.

The distinguished panel comprised of **Dr. Peggy Whitson** – Astronaut & Vice President, Human Spaceflight, Axiom Space; **Dr. BHM Darukesha** – Senior Scientist, Human Space Flight Center, ISRO; **Dr. Shireesh Srivastava** – Group Leader, Systems Biology for Biofuel Group, ICgeb; **Dr. Dariusz Zapala** – Co-founder & CSO, Cortivision and the Moderator **Pearly Pandya** – Director, International Government Business, Axiom Space.

**Pearly Pandya** opened the session by providing an overview of Axiom Mission 4, highlighting it as a landmark commercial space mission that brought together astronauts from the United States, India, Poland, and Hungary. She noted that the crew spent 20 days aboard the International Space Station, completing 320 orbits around Earth, travelling over 13.5 million kilometres, and conducting more than 60 scientific investigations. She emphasized that commercial missions such as Ax-4 are

creating unprecedented opportunities for international collaboration and expanding access to space-based research.

**Dr. Peggy Whitson** highlighted how the mission successfully integrated scientific objectives from multiple countries into a single collaborative programme. She explained that Ax-4 enabled research across cell biology, cancer research, human physiology, plant science, and other biomedical disciplines, demonstrating how microgravity provides unique conditions for scientific discovery. She also emphasized Axiom Space's vision of enabling broader global participation in space research through commercial missions.

**Dr. BHM Darukesh**a presented India's contribution to Axiom Mission 4, noting that seven experiments from Indian principal investigators were selected for the mission, six of which focused on biological sciences. He explained that these studies investigate the behaviour of edible microalgae, crop seeds, microorganisms, and muscle biology under microgravity conditions. The findings are expected to contribute not only to future long-duration human space missions but also to advancements in agriculture, nutrition, and biotechnology applications on Earth.

**Dr. Shireesh Srivastava** shared insights into his team's research on cyanobacteria, highlighting their potential role in enabling sustainable human habitation in space. He explained how these microorganisms can recycle carbon dioxide and nitrogen, produce oxygen, and generate protein-rich biomass, making them valuable for supporting future lunar and Mars missions. The research also demonstrates how biological systems developed for space exploration can contribute to sustainable biomanufacturing and circular bioeconomy solutions on Earth.

**Dr. Dariusz Zapala** discussed the application of functional near-infrared spectroscopy (fNIRS) for monitoring astronauts' brain activity during spaceflight. He highlighted how the lightweight, non-invasive technology enables real-time assessment of cognitive function in microgravity, supporting astronaut health while offering significant applications for neurological research and clinical healthcare on Earth.

The webinar highlighted Axiom Mission 4 as a milestone in commercial space exploration and biomedical innovation, demonstrating the immense potential of microgravity research in advancing drug discovery, precision healthcare, and biomanufacturing. It also emphasized the importance of international collaboration in enabling India's biotechnology ecosystem to participate in the emerging global space bioeconomy and translate space-based research into real-world healthcare solutions.

Click here to watch the recording: <https://www.youtube.com/watch?v=TnT5JU9inc0>

## Highlights of the webinar “Indo–Iowa–U.S. Biosciences Collaboration” held on 11<sup>th</sup> June



The **Indo–American Chamber of Commerce (IACC)**, in partnership with the **Iowa Economic Development Authority (IEDA)** and with support from the **Iowa Biotechnology Association (IowaBio)** and **ABLE**, successfully

organized the **Indo–Iowa–U.S. Biosciences Collaboration Webinar**, bringing together industry leaders from India and the United States to explore opportunities for collaboration in biotechnology, innovation, investment, and market access. The engaging panel discussion, moderated by Ms. Jessica Hyland featured esteemed industry leaders Jessica Hyland – Executive Director, Iowa Biotechnology Association (IowaBio); Dr. Michael Schultz – Chief Science Officer & Co-Founder, Perspective Therapeutics; Kavilash Chawla – Chief Growth Officer, PowerPollen Inc.; Jennifer Igou – President, North America, Camlin Fine Sciences (CFS) and Mr. G S Krishnan – Hon. President, ABLE.

**Representing ABLE, Mr. G S Krishnan** highlighted ABLE's pivotal role in advancing India's biotechnology ecosystem through policy advocacy, industry engagement, and ecosystem development over the past two decades. He spoke about the significance of the India BioEconomy Report, an ABLE initiative that has helped quantify biotechnology's contribution to the Indian economy while enabling states to identify new opportunities for growth across BioPharma, BioIndustrial, and BioServices. Mr. Krishnan emphasized India's immense biotechnology potential, driven by its strong innovation ecosystem, world-class research institutions, and rapidly growing bioeconomy. He also underscored the importance of international collaborations, noting that partnerships between organizations such as ABLE and IowaBio can facilitate startup connections, knowledge exchange, technology partnerships, and business opportunities, further strengthening the Indo–U.S. biotechnology relationship.

Discussions focused on emerging trends shaping the future of biotechnology, opportunities for cross-border research and innovation, pathways for Indian companies to enter and expand in the U.S. market, and the growing investment landscape in the biosciences sector. The session underscored the importance of building strong international partnerships to accelerate innovation, commercialization, and sustainable growth across the global biotechnology ecosystem. Click here for the webinar recording: <https://www.youtube.com/watch?v=Fv-un8V6Y-4>

## Industry News

### *EY Biotech Beyond Borders 2026 flags resilient biotech growth, tighter funding and Asia's rising role*

**EY's Biotech Beyond Borders 2026** report said the biotech industry posted its third consecutive year of growth, with revenue up 13% to \$232 billion in 2025, even as financing pressure, patent cliffs and geopolitical uncertainty continued to weigh on the sector. The report also said biotech financing remained relatively strong, with \$68.5 billion raised in 2025, up 11% from 2024, while capital increasingly flowed toward later-stage assets and larger, higher-conviction deals.

A key theme was the industry's shift toward more balanced portfolios and new financing structures. EY noted that companies leaned more heavily on alliances and acquisitions to offset loss of exclusivity and build resilience, while some biotechs adopted synthetic royalty agreements and other innovative contracting models to manage market pressure. M&A activity also rebounded, with oncology and neurology emerging as major dealmaking themes.

The report also said that the capital had become more selective. Late-stage VC dominated funding activity, while early-stage value and volume fell, reinforcing a widening split between better-capitalized biotechs and smaller players. M&A activity rebounded as companies leaned more heavily on acquisitions and alliances to build stronger portfolios and offset patent cliffs and loss of exclusivity.

The report placed strong emphasis on Asia, particularly China. EY said 39% of US biobucks flowed to China, while more than 88% of AI-related biotech investment was concentrated in R&D, especially drug target identification, drug design and clinical trial patient recruitment. That signaled Asia's growing importance not just as a market, but as a core source of innovation and partnering activity.

EY also pointed to regulatory shifts and "repatriating" trends, with industry leaders pledging up to US\$370 billion toward domestic manufacturing in response to tariffs and supply-chain concerns. Overall, the report portrayed a sector that remained fundamentally strong, but one that needed to stay agile as capital, regulation and innovation all moved in new directions.

[Click here to Read more](#)

*Source: Ernst & Young Global Limited*

***Ipca Labs ties up with biotech firm to develop cancer and autoimmune disease treatments***



**Mumbai-based Ipca Laboratories** and **Bhami's Research Laboratory (BRL)** have entered into a definitive global licensing agreement that grants Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform.

The collaboration will focus on the development and commercialisation of multiple monoclonal antibody products targeting oncology and inflammatory diseases.

Under the agreement, BRL will undertake proof-of-concept and formulation development activities, while Ipca will be responsible for further research and development, clinical trials, commercial manufacturing and product launches.

The licensing arrangement covers worldwide rights. BRL will receive a defined milestone fee related to the technology transfer and will also earn royalties on net sales upon commercialisation of the products.

Commenting on the partnership, Pranay Godha, Managing Director and Chief Executive Officer of Ipca Laboratories, said the collaboration combines Ipca's scientific capabilities with BRL's formulation platform to accelerate the development of affordable biologics for patients battling cancer and autoimmune diseases globally.

BRL Co-founder and Chief Executive Officer Dr Suryakanth M Pai said the partnership would expand the reach of the company's proprietary and patented subcutaneous protein delivery platform technology and help develop differentiated biologics for global markets. He added that the collaboration is aimed at making patient care more convenient, affordable and safe.

Akhil Shah, Director and Chief Executive Officer of WeTranslate, said BRL has built a differentiated formulation technology platform, while Ipca brings the scale, expertise and global reach required for commercialisation. He added that WeTranslate was pleased to support the collaboration and its potential impact on biologic drug delivery.

*Source: CNBC TV*

## ***Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis***

Wockhardt announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens. ZAYNICH™ previously received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.

“The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens. The FDA approval of ZAYNICH™ is a monumental step forward in validating a new option for these underserved populations,” said Dennis Deruelle, MD, FHM, Chief Medical Officer at Wockhardt. “This milestone underscores our commitment to addressing critical unmet needs and offers a profound sense of hope to the families we are working to serve.”

“This approval is a significant realization of our mission to provide patients with novel antibiotics that help to address one of the most urgent global health threats—antimicrobial resistance,” said Dr. Habil F. Khorakiwala, Founder and Chairman of Wockhardt Group. “Furthermore, ZAYNICH™ is the first New Chemical Entity fully developed and commercialized by an Indian pharmaceutical company to receive an FDA approval, representing a historic milestone not only for Wockhardt, but for the Indian pharmaceutical industry.”

ZAYNICH™, unlike most other beta-lactam combinations, targets multiple penicillin binding proteins (PBP 1a/b, 2 and 3) simultaneously. This unique, multi-target synergy provides bactericidal activity against the most challenging drug-resistant Gram-negative bacteria for which there are currently very limited treatment options.

“Multidrug-resistant bacterial infections are a substantial burden for patients and the healthcare system, as patients with these infections typically require longer, more intensive care, and are at increased risk of lifethreatening complications,” explained Keith Kaye, MD, MPH, Professor of Medicine and Division Chief for Infectious Diseases at Rutgers Robert Wood Johnson Medical School. “There is an ongoing need for new antibiotics to combat these drug-resistant pathogens, and we are pleased that this approval means patients will soon have an exciting unique option that is urgently needed in the US and worldwide.”

cUTI is responsible for over 600,000 hospitalizations in the U.S. annually. A growing number of cUTIs are caused by antimicrobial resistant bacteria, including multidrug-

resistant bacteria, a leading cause of bacteremia and associated with significant morbidity and mortality and a burden on the health care system.

The FDA approval was based, in part, on the results from ENHANCE-1, a Phase 3, randomized, double-blind, multicenter study which evaluated the efficacy, safety and tolerability of ZAYNICH™ compared with meropenem in the treatment of hospitalized adults with cUTI or acute pyelonephritis (AP). ZAYNICH™ demonstrated efficacy at the primary endpoint, achieving a composite clinical cure and microbiological response rate of 89.0% versus 68.4% for meropenem Treatment difference 20.6% (95% CI; 12.3, 29.5). ZAYNICH™ was generally well tolerated in the phase 3 study. The study enrolled 530 patients from the U.S., Europe, LATAM, China and India, and spanned across 64 sites.

ZAYNICH® was approved by the Drugs Controller General of India (DCGI) on May 27, 2026. Wockhardt has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency.

ZAYNICH™ is a multi- penicillin-binding protein™ targeting combination of the 4th generation cephalosporin cefepime and zidebactam working synergistically against the most challenging multidrug-resistant Gramnegative bacteria.

In the Phase 3 ENHANCE-1 clinical trial, ZAYNICH™ demonstrated higher combined clinical cure and microbiologic response (composite endpoint) at the test of cure (TOC) visit versus meropenem, 89.0% vs 68.4% respectively and was generally well tolerated.

More than 2.8 million antimicrobial-resistant infections occur each year in the U.S., resulting in more than 35,000 deaths.

*Source: Wockhardt Press Release*

---

## ABLE Welcomes Its New Members



**ASSOCIATION OF  
BIOTECHNOLOGY  
LED ENTERPRISES  
(ABLE)**

Comments and questions are welcome and should be addressed to:

Email  
[info@ableindia.org.in](mailto:info@ableindia.org.in)

Website  
[www.ableindia.in](http://www.ableindia.in)

[Twitter](#)

[LinkedIn](#)

Address  
No.123/C, 16th  
Main Road 4th  
Block, 5th Cross,  
Koramangala,  
Bangalore-560 034,  
India

Tel.:  
+91-80-41636853



## FOCUS AREAS



[www.ableindia.in](http://www.ableindia.in)